Evidence map›Paper›PMID 28432428›Full record

ReviewWiener klinische Wochenschrift2017

Tranexamic acid for treatment and prophylaxis of bleeding and hyperfibrinolysis.

Ingrid Pabinger, Dietmar Fries, Herbert Schöchl, Werner Streif, Wolfgang Toller

3 registry-linked trialsOpen access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Wiener klinische Wochenschrift, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 59 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed, 7 pooled it
6.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05340205 phase4completednot on this mapstarted 2022, after this paper: background citation

The Efficacy and Safety of Intrauterine Misoprostol Versus Intravenous Tranexamic Acid in Reducing Blood Loss During and After Cesarean Delivery in Patients With Placenta Previa: A Randomized Controlled Trial

TypeinterventionalSponsorCairo UniversityRan2022 to 2023Enrolled81ConditionsPlacenta PreviaArmsTranexamic acid, Misoprostol, Oxytocin
NCT06266546 phase3active not recruitingnot on this mapstarted 2024, after this paper: background citation

Prophylactic Endobronchial Tranexamic Acid to Reduce Bleeding in Transbronchial Cryobiopsy

TypeinterventionalSponsorYoussef YammineRan2024 to 2028Enrolled100ConditionsHemorrhage Lung, Endobronchial MassArmsTranexamic acid
NCT06781021 naenrolling by invitationnot on this mapstarted 2024, after this paper: background citation

The Effect of Tranexamic Acid Vs Torniquet on Visual Clarity in Knee Arthroscopic Anterior Cruciate Ligament (ACL) Reconstruction

TypeinterventionalSponsorThe University of The West IndiesRan2024 to 2026Enrolled60ConditionsACL TearsArmsTourniquet, TXA
3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 7 syntheses or guidelines pooled it, 184 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Effect of Prophylactic Intraoperative Tranexamic Acid on Postpartum Blood Loss Following Cesarean Section at a Single Center.Medical science monitor : international medical journal of experimental and clinical research · 2025
    Trial
  9. Trial
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Observational
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Ingrid PabingerClinical Department of Hematology and Hemostaseology, Medical University Vienna, Vienna, Austria. ingrid.pabinger@meduniwien.ac.at.
Dietmar FriesDepartment of General and Surgical Intensive Care Medicine, Medical University Innsbruck, Innsbruck, Austria.
Herbert SchöchlDepartment of Anesthesiology and Intensive Care Medicine, AUVA Accident Hospital Salzburg, Salzburg, Austria.
Werner StreifDepartment of Children and Adolescents Medicine, Medical University Innsbruck, Innsbruck, Austria.
Wolfgang TollerDepartment of Anesthesiology and Intensive Care Medicine, Medical University Graz, Graz, Austria.
Innsbruck Medical University · ATMedical University of Graz · ATMedical University of Vienna · ATParacelsus Medical University · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Uncontrolled massive bleeding with subsequent derangement of the coagulation system is a major challenge in the management of both surgical and seriously injured patients. Under physiological conditions activators and inhibitors of coagulation regulate the sensitive balance between clot formation and fibrinolysis. In some cases, excessive and diffuse bleeding is caused by systemic activation of fibrinolysis, i. e. hyperfibrinolysis (HF). Uncontrolled HF is associated with a high mortality. Polytrauma patients and those undergoing surgical procedures involving organs rich in plasminogen proactivators (e. g. liver, kidney, pancreas, uterus and prostate gland) are at a high risk for HF. Antifibrinolytics, such as tranexamic acid (TXA) are used for prophylaxis and treatment of bleeding caused by a local or generalized HF as well as other hemorrhagic conditions. TXA is a synthetic lysine analogue that has been available in Austria since 1966. TXA is of utmost importance in the prevention and treatment of traumatic and perioperative bleeding due to the resulting reduction in perioperative blood loss and blood transfusion requirements. The following article presents the different fields of application of TXA with particular respect to indications and dosages, based on a literature search and on current guidelines.

Indexed as

Practice Guidelines as TopicAntifibrinolytic AgentsBlood CoagulationBlood Coagulation DisordersDose-Response Relationship, DrugFibrinolysisHematologyHemorrhageHumansTranexamic AcidTreatment OutcomeAntifibrinolytic AgentsTranexamic AcidBleedingHyperfibrinolysisSurgeryTranexamic acidTrauma

Identifiers

PMID28432428
PMCPMC5429347
OpenAlexW2605570425

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.